Region
Featured experience
Atairos investment in the parent company of the Aston Villa Football Club
We are advising Atairos on the minority investment
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
$100 million investment by consortium in Airbus subsidiary AALTO
We are advising Airbus on the transaction
Haleon $3 billion secondary placing of ordinary shares
The private placement included 700,000,000 ordinary shares
Mizuho Financial Group $2 billion senior notes offering
Davis Polk advised the joint bookrunners and lead managers in connection with Mizuho Financial Group, Inc.’s SEC-registered…
Tencent Music $800 million debut SEC-registered notes offering
Davis Polk advised Tencent Music Entertainment Group on its debut SEC-registered notes offering, consisting of $300 million…
Emirate of Abu Dhabi $5 billion notes offering
Davis Polk advised the joint lead managers in connection with a Rule 144A/Regulation S offering by the Emirate of Abu Dhabi…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate…
SEB $2 billion notes offering
Davis Polk advised the joint book-running managers on the Rule 144A/Regulation S offering by SEB of $1 billion…
NatWest Group $850 million subordinated Tier 2 notes offering
Davis Polk advised NatWest Group plc (formerly The Royal Bank of Scotland Group plc), a public limited company incorporated…
Delek $2.25 billion senior secured project notes offering
Davis Polk advised Delek Drilling Limited Partnership, as sponsor, on the Rule 144A offering by its special-purpose vehicle…
Dufry $311 million going-private acquisition of Hudson
Davis Polk is advising Dufry AG in connection with its proposed acquisition of all the equity interests in Hudson Ltd. it…
Cellnex Telecom €4 billion equity offering
Davis Polk advised Cellnex Telecom, S.A. as to U.S. law in connection with its offering of 101,382,140 new ordinary shares…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…